Abstract
Background:Severe pneumonia is one of the common acute diseases caused by pathogenic microorganism infection, especially by pathogenic bacteria, leading to sepsis with a high morbidity and mortality rate. However, the existing bacteria cultivation method cannot satisfy current clinical needs requiring rapid identification of bacteria strain for antibiotic selection. Therefore, developing a sensitive liquid biopsy system demonstrates the enormous value of detecting pathogenic bacterium species in pneumonia patients.Methods:In this study, we developed a tool named Species-Specific Bacterial Detector (SSBD, pronounce as ‘speed’) for detecting selected bacterium. Newly designed diagnostic tools combining specific DNA-tag screened by our algorithm and CRISPR/Cas12a, which were first tested in the lab to confirm the accuracy, followed by validating its specificity and sensitivity via applying on bronchoalveolar lavage fluid (BALF) from pneumonia patients. In the validation I stage, we compared the SSBD results with traditional cultivation results. In the validation II stage, a randomized and controlled clinical trial was completed at the ICU of Nanjing Drum Tower Hospital to evaluate the benefit SSBD brought to the treatment.Results:In the validation stage I, 77 BALF samples were tested, and SSBD could identify designated organisms in 4 hr with almost 100% sensitivity and over 87% specific rate. In validation stage II, the SSBD results were obtained in 4 hr, leading to better APACHE II scores (p=0.0035, ANOVA test). Based on the results acquired by SSBD, cultivation results could deviate from the real pathogenic situation with polymicrobial infections. In addition, nosocomial infections were found widely in ICU, which should deserve more attention.Conclusions:SSBD was confirmed to be a powerful tool for severe pneumonia diagnosis in ICU with high accuracy.Funding:National Natural Science Foundation of China. The National Key Scientific Instrument and Equipment Development Project. Project number: 81927808.Clinical trial number:This study was registered at https://clinicaltrials.gov/ (NCT04178382).
Full Text
Topics from this Paper
Conventional Culture Test
Sequential Organ Failure Assessment Scores
Validation Stage
Experiment Group
FilmArray Pneumonia Panel
+ Show 5 more
Create a personalized feed of these topics
Get StartedTalk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Similar Papers
Chinese critical care medicine
Aug 1, 2016
BMC Infectious Diseases
Jan 15, 2021
International Medicine and Health Guidance News
Apr 15, 2013
Italian Journal of Pediatrics
Apr 7, 2023
eLife
Oct 7, 2022
International Journal of Emergency Medicine
Jul 23, 2021
Nigerian Journal of Clinical Practice
Jan 1, 2016
JAMA
Aug 18, 2020
Infection and Drug Resistance
Dec 1, 2022
Turkish Thoracic Journal/Türk Toraks Dergisi
Apr 1, 2015
Chinese Medical Journal
Dec 3, 2020
Frontiers in Cellular and Infection Microbiology
Mar 27, 2023
Chinese critical care medicine
Jul 1, 2020
Burns & Trauma
Jan 1, 2020
TURKISH JOURNAL OF MEDICAL SCIENCES
Jan 1, 2015